TY  - JOUR
AU  - Lindsay, Holly B
AU  - Massimino, Maura
AU  - Avula, Shivaram
AU  - Stivaros, Stavros
AU  - Grundy, Richard
AU  - Metrock, Katie
AU  - Bhatia, Aashim
AU  - Fernández-Teijeiro, Ana
AU  - Chiapparini, Luisa
AU  - Bennett, Jeffrey
AU  - Wright, Karen
AU  - Hoffman, Lindsey M
AU  - Smith, Amy
AU  - Pajtler, Kristian
AU  - Poussaint, Tina Young
AU  - Warren, Katherine E
AU  - Foreman, Nicholas K
AU  - Mirsky, David M
TI  - Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
JO  - The lancet  / Oncology
VL  - 23
IS  - 8
SN  - 1470-2045
CY  - London
PB  - The Lancet Publ. Group
M1  - DKFZ-2022-01586
SP  - e393-e401
PY  - 2022
N1  - 2022 Aug;23(8):e393-e401
AB  - Response criteria for paediatric intracranial ependymoma vary historically and across different international cooperative groups. The Response Assessment in the Pediatric Neuro-Oncology (RAPNO) working group, consisting of an international panel of paediatric and adult neuro-oncologists, neuro-radiologists, radiation oncologists, and neurosurgeons, was established to address both the issues and the unique challenges in assessing the response in children with CNS tumours. We established a subcommittee to develop response assessment criteria for paediatric ependymoma. Current practice and literature were reviewed to identify major challenges in assessing the response of paediatric ependymoma to clinical trial therapy. For areas in which data were scarce or unavailable, consensus was reached through an iterative process. RAPNO response assessment recommendations include assessing disease response on the basis of changes in tumour volume, and using event-free survival as a study endpoint for patients entering clinical trials without bulky disease. Our recommendations for response assessment include the use of brain and spine MRI, cerebral spinal fluid cytology, neurological examination, and steroid use. Baseline postoperative imaging to assess for residual tumour should be obtained 24-48 h after surgery. Our consensus recommendations and response definitions should be prospectively validated in clinical trials.
LB  - PUB:(DE-HGF)16
C6  - pmid:35901835
DO  - DOI:10.1016/S1470-2045(22)00222-4
UR  - https://inrepo02.dkfz.de/record/180837
ER  -